Dyax/Bayer Schering Ink Antibody Discovery Agreement
This article was originally published in The Pink Sheet Daily
Executive Summary
External licensing and discovery agreements support internal pipeline growth, goal of total integration, Dyax CEO tells “The Pink Sheet” DAILY.
You may also be interested in...
Jerini Submits Icatibant NDA; Asks FDA For Priority Review
Priority review would give the company’s hereditary angioedema treatment a user fee date in late April/early May 2008, firm tells “The Pink Sheet” DAILY.
Jerini Submits Icatibant NDA; Asks FDA For Priority Review
Priority review would give the company’s hereditary angioedema treatment a user fee date in late April/early May 2008, firm tells “The Pink Sheet” DAILY.
Jerini’s Icatibant Could Be Second To Market For Hereditary Angioedema
Jerini submits NDA for bradykinin blocker just over two months after Lev Pharmaceuticals’ Cinryze was filed.